-

Shareholder Alert: Robbins LLP is Investigating GoodRx Holdings, Inc. (GDRX) on Behalf of Shareholders

SAN DIEGO & SANTA MONICA, Calif.--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP is investigating GoodRx Holdings, Inc. (NASDAQ: GDRX) on behalf of shareholders to determine whether certain GoodRx officers and directors violated the Securities Exchange Act of 1934 and breached their fiduciary duties to the Company. GoodRx is a holding company that owns and operates a U.S. consumer-focused digital healthcare platform.

If you suffered a loss due to GoodRx Holdings, Inc.'s misconduct, click here.

GoodRx Holdings, Inc. (GDRX) Misled Shareholders Regarding its Business Prospects

According to a class action complaint filed against GoodRx, Defendants timed the Company's initial public offering ("IPO") to happen just before Amazon.com, Inc. announced its online pharmaceutical business that would compete with GoodRx, which maximized the amount of money the selling stockholders could raise in the IPO and artificially inflated GoodRx's stock price.

GoodRx closed its IPO on September 25, 2020, selling 39.8 million shares for $33 per share, generating over $1.3 billion in gross offering proceeds. In its Registration Statement, GoodRx touted its successes in growing market share and stated that it is "a market leader with a significant scale and brand advantage over our competitors. Our growth accelerates self-reinforcing network effects that further strengthen our competitive position." However, at the time these statements were made, defendants knew that Amazon was about to enter the online prescription medication ordering and fulfillment business because of the Company's close relationship with Amazon and reliance on Amazon Web Services to support the Company's platform. On November 17, 2020, Amazon announced two new pharmacy offerings, which would compete directly with GoodRx's platform. On this news, GoodRx's stock declined 23%, erasing more than $4 billion of the Company's market capitalization.

GoodRx Holdings, Inc. (GDRX) shareholders have legal options. All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

Contact us to learn more:
Lauren Levi
(800) 350-6003
llevi@robbinsllp.com
Shareholder Information Form

Robbins LLP is a nationally recognized leader in shareholder rights law. To be notified if a class action against GoodRx Holdings, Inc. settles or to receive free alerts about companies engaged in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Lauren Levi
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
llevi@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

More News From Robbins LLP

Investor Notice: Shareholder Rights Law Firm Robbins LLP Informs Investors of the uniQure N.V. Securities Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired uniQure N.V. (NASDAQ: QURE) ordinary shares between September 24, 2025 and October 31, 2025. uniQure is a biotechnology company developing gene therapies for rare diseases. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP is Investigating Allegations that un...

Investor Notice: Shareholder Rights Law Firm Robbins LLP Informs Investors of the POMDoctor Ltd. Securities Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired POMDoctor, Ltd. (NASDAQ: POM) securities between October 9, 2025 and December 11, 2025. POMDoctor claims to be "a leading online medical services platform for chronic diseases in China." For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP is Investigating Alleg...

Investor Notice: Shareholder Rights Law Firm Robbins LLP Informs Investors of the Inovio Pharmaceuticals, Inc. Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all persons that purchased or otherwise acquired Inovio Pharmaceuticals, Inc. (NASDAQ: INO) securities between October 10, 2023 and December 26, 2025. Inovio is a biotechnology company focused on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with, inter alia, human papillomavirus (“HPV”). For more information, submit a...
Back to Newsroom